Icosavax, a Phase 1 biotech developing vaccines for respiratory diseases, raised $182 million by offering 12.1 million shares at $15, within the range of $14 to $16. The company offered 2.1 million more shares than anticipated.
Icosavax is developing its virus-like particle, or VLP, platform technology to develop vaccines against infectious diseases, with an initial focus on life threatening respiratory diseases. The company's pipeline includes vaccines programs targeting some of the most prevalent viral causes of pneumonia. The company's lead program is IVX-A12, a bivalent candidate targeting both respiratory syncytial virus, or RSV, and human metapneumovirus, or hMPV.
Icosavax plans to list on the Nasdaq under the symbol ICVX. Jefferies, Cowen, Evercore ISI, and William Blair acted as joint bookrunners on the deal.
